Purification of a conjugated polysaccharide vaccine using tangential flow diafiltration

Parinaz Emami, Seyed Pouria Motevalian, Erin Pepin, Andrew Zydney

Research output: Contribution to journalArticle

Abstract

Conjugated vaccines prepared from the capsular polysaccharide of Streptococcus pneumoniae can provide immunization against invasive pneumococcal disease, meningitis, and otitis media. One of the critical steps in the production of these vaccines is the removal of free (unreacted) polysaccharides from the protein-polysaccharide conjugate. Experimental studies were performed to evaluate the effects of membrane pore size, filtrate flux, and solution conditions on the transmission of both the conjugate and free polysaccharide through different ultrafiltration membranes. Conjugate purification was done using diafiltration performed in a linearly-scalable tangential flow filtration cassette. More than 98% of the free polysaccharide was removed within a 5-diavolume diafiltration process, which is a significant improvement over previously reported results for purification of similar conjugated vaccines. These results clearly demonstrate the opportunities for using ultrafiltration/diafiltration for the final purification of conjugated vaccine products.

Original languageEnglish (US)
Pages (from-to)591-597
Number of pages7
JournalBiotechnology and Bioengineering
Volume116
Issue number3
DOIs
StatePublished - Mar 1 2019

Fingerprint

Vaccines
Polysaccharides
Purification
Ultrafiltration
Pneumococcal Meningitis
Immunization
Membranes
Otitis Media
Streptococcus pneumoniae
Pore size
Fluxes
Proteins

All Science Journal Classification (ASJC) codes

  • Biotechnology
  • Bioengineering
  • Applied Microbiology and Biotechnology

Cite this

Emami, Parinaz ; Motevalian, Seyed Pouria ; Pepin, Erin ; Zydney, Andrew. / Purification of a conjugated polysaccharide vaccine using tangential flow diafiltration. In: Biotechnology and Bioengineering. 2019 ; Vol. 116, No. 3. pp. 591-597.
@article{cec72d0568f24f40abc2df601c76378e,
title = "Purification of a conjugated polysaccharide vaccine using tangential flow diafiltration",
abstract = "Conjugated vaccines prepared from the capsular polysaccharide of Streptococcus pneumoniae can provide immunization against invasive pneumococcal disease, meningitis, and otitis media. One of the critical steps in the production of these vaccines is the removal of free (unreacted) polysaccharides from the protein-polysaccharide conjugate. Experimental studies were performed to evaluate the effects of membrane pore size, filtrate flux, and solution conditions on the transmission of both the conjugate and free polysaccharide through different ultrafiltration membranes. Conjugate purification was done using diafiltration performed in a linearly-scalable tangential flow filtration cassette. More than 98{\%} of the free polysaccharide was removed within a 5-diavolume diafiltration process, which is a significant improvement over previously reported results for purification of similar conjugated vaccines. These results clearly demonstrate the opportunities for using ultrafiltration/diafiltration for the final purification of conjugated vaccine products.",
author = "Parinaz Emami and Motevalian, {Seyed Pouria} and Erin Pepin and Andrew Zydney",
year = "2019",
month = "3",
day = "1",
doi = "10.1002/bit.26867",
language = "English (US)",
volume = "116",
pages = "591--597",
journal = "Biotechnology and Bioengineering",
issn = "0006-3592",
publisher = "Wiley-VCH Verlag",
number = "3",

}

Purification of a conjugated polysaccharide vaccine using tangential flow diafiltration. / Emami, Parinaz; Motevalian, Seyed Pouria; Pepin, Erin; Zydney, Andrew.

In: Biotechnology and Bioengineering, Vol. 116, No. 3, 01.03.2019, p. 591-597.

Research output: Contribution to journalArticle

TY - JOUR

T1 - Purification of a conjugated polysaccharide vaccine using tangential flow diafiltration

AU - Emami, Parinaz

AU - Motevalian, Seyed Pouria

AU - Pepin, Erin

AU - Zydney, Andrew

PY - 2019/3/1

Y1 - 2019/3/1

N2 - Conjugated vaccines prepared from the capsular polysaccharide of Streptococcus pneumoniae can provide immunization against invasive pneumococcal disease, meningitis, and otitis media. One of the critical steps in the production of these vaccines is the removal of free (unreacted) polysaccharides from the protein-polysaccharide conjugate. Experimental studies were performed to evaluate the effects of membrane pore size, filtrate flux, and solution conditions on the transmission of both the conjugate and free polysaccharide through different ultrafiltration membranes. Conjugate purification was done using diafiltration performed in a linearly-scalable tangential flow filtration cassette. More than 98% of the free polysaccharide was removed within a 5-diavolume diafiltration process, which is a significant improvement over previously reported results for purification of similar conjugated vaccines. These results clearly demonstrate the opportunities for using ultrafiltration/diafiltration for the final purification of conjugated vaccine products.

AB - Conjugated vaccines prepared from the capsular polysaccharide of Streptococcus pneumoniae can provide immunization against invasive pneumococcal disease, meningitis, and otitis media. One of the critical steps in the production of these vaccines is the removal of free (unreacted) polysaccharides from the protein-polysaccharide conjugate. Experimental studies were performed to evaluate the effects of membrane pore size, filtrate flux, and solution conditions on the transmission of both the conjugate and free polysaccharide through different ultrafiltration membranes. Conjugate purification was done using diafiltration performed in a linearly-scalable tangential flow filtration cassette. More than 98% of the free polysaccharide was removed within a 5-diavolume diafiltration process, which is a significant improvement over previously reported results for purification of similar conjugated vaccines. These results clearly demonstrate the opportunities for using ultrafiltration/diafiltration for the final purification of conjugated vaccine products.

UR - http://www.scopus.com/inward/record.url?scp=85059256117&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85059256117&partnerID=8YFLogxK

U2 - 10.1002/bit.26867

DO - 10.1002/bit.26867

M3 - Article

C2 - 30450582

AN - SCOPUS:85059256117

VL - 116

SP - 591

EP - 597

JO - Biotechnology and Bioengineering

JF - Biotechnology and Bioengineering

SN - 0006-3592

IS - 3

ER -